Index of the Week.
Every Friday we pick one custom index that earned the slot: original thesis, defensible rule, holdings worth defending. The award goes to the index, not the person who typed the prompt. Browse the back catalogue.
Quality Compounders ex-Tech 30
Thirty global compounders with ROIC above 20% and zero exposure to the Magnificent Seven, on a 5-year backtest that quietly clears SPY.
Earlier awards
Defence ex-Arms 20
Week of 16 May 2026Twenty defence and aerospace names with no exposure to cluster munitions, nuclear delivery systems or anti-personnel mines, weighted by 3-year backlog growth.
CAGR 21.4%·Sharpe 0.97·Max DD -18.6%·May 2021 to May 2026 (5Y)Dividend Aristocrats ex-Tobacco 25
Week of 9 May 2026The 25-year dividend-growth list with tobacco names dropped and the savings redistributed by FCF coverage, not yield.
CAGR 9.4%·Sharpe 0.71·Max DD -15.8%·May 2021 to May 2026 (5Y)AI Infrastructure ex-Magnificent-Seven 25
Week of 2 May 2026Twenty-five picks-and-shovels names behind the AI buildout, with Nvidia, Microsoft, Alphabet, Amazon, Meta, Apple and Tesla deliberately excluded.
CAGR 26.7%·Sharpe 0.91·Max DD -32.1%·May 2023 to May 2026 (3Y)European Champions 30
Week of 25 Apr 2026Thirty European-listed global category leaders, sales-weighted, with a hard cap on bank exposure.
CAGR 11.2%·Sharpe 0.74·Max DD -19.8%·Apr 2021 to Apr 2026 (5Y)FTSE 100 High-FCF 25
Week of 18 Apr 2026Twenty-five FTSE 100 names with FCF yield above 7% and buyback yield above 3%, weighted by combined shareholder yield.
CAGR 12.7%·Sharpe 0.74·Max DD -17.2%·Apr 2021 to Apr 2026 (5Y)Sovereign AI 15
Week of 11 Apr 2026Fifteen names with disclosed government AI contracts in the US, UK, France, Germany, Japan, India and the Gulf, weighted by contract value.
CAGR 31.6%·Sharpe 1.16·Max DD -24.9%·Apr 2023 to Apr 2026 (3Y)Nuclear Renaissance 20
Week of 4 Apr 2026Twenty names across uranium miners, fuel cycle, reactor builders, SMR developers and utilities running existing fleets, weighted by enrichment capacity exposure.
CAGR 28.2%·Sharpe 0.83·Max DD -38.4%·Apr 2023 to Apr 2026 (3Y)UK Mid-Cap Quality 25
Week of 28 Mar 2026Twenty-five FTSE 250 names with ROIC above 15%, leverage below 1.5x and 5-year revenue growth above 7%, capped at 6% per name.
CAGR 14.1%·Sharpe 0.72·Max DD -22.4%·Mar 2021 to Mar 2026 (5Y)Healthcare ex-China 30
Week of 21 Mar 2026Thirty global healthcare names with under 10% China revenue exposure and no Chinese supply chain dependence above 20% of API sourcing.
CAGR 11.7%·Sharpe 0.78·Max DD -16.2%·Mar 2021 to Mar 2026 (5Y)